Equities analysts expect Solid Biosciences (NASDAQ:SLDB) to post earnings of ($0.43) per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Solid Biosciences’ earnings, with the highest EPS estimate coming in at ($0.41) and the lowest estimate coming in at ($0.45). The business is expected to report its next earnings results on Thursday, July 5th.
On average, analysts expect that Solid Biosciences will report full-year earnings of ($1.92) per share for the current fiscal year, with EPS estimates ranging from ($2.24) to ($1.67). For the next year, analysts forecast that the business will post earnings of ($1.88) per share, with EPS estimates ranging from ($2.24) to ($1.53). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that cover Solid Biosciences.
Several brokerages have issued reports on SLDB. JPMorgan Chase lowered shares of Solid Biosciences from a “neutral” rating to an “underweight” rating and set a $28.00 price target on the stock. in a research note on Thursday, March 15th. Leerink Swann began coverage on shares of Solid Biosciences in a research note on Tuesday, February 20th. They issued an “outperform” rating and a $36.00 price target on the stock. Goldman Sachs began coverage on shares of Solid Biosciences in a research note on Tuesday, February 20th. They issued a “neutral” rating and a $31.00 price target on the stock. Nomura began coverage on shares of Solid Biosciences in a research note on Tuesday, February 20th. They issued a “buy” rating and a $52.00 price target on the stock. Finally, Instinet began coverage on shares of Solid Biosciences in a research note on Tuesday, February 20th. They issued a “buy” rating and a $52.00 price target on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company. Solid Biosciences currently has an average rating of “Hold” and a consensus target price of $33.67.
SLDB stock traded up $0.04 during midday trading on Thursday, hitting $10.09. The company’s stock had a trading volume of 82,815 shares, compared to its average volume of 393,069. Solid Biosciences has a twelve month low of $6.83 and a twelve month high of $33.74. The firm has a market capitalization of $353.70 and a P/E ratio of -3.50.
Solid Biosciences Company Profile
Solid Biosciences Inc, a life science company, engages in identifying and developing various therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, an adeno-associated viral vector-mediated gene therapy that is in Phase I/II clinical trials to restore functional dystrophin protein expression in patients' muscles.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.